Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Cardioprotection Comparison: GLP-1 Drugs Show Similar Effects
S
Shotlee
Health & Wellness Team
2 min read
Preparing your Shotlee experience
Research comparing tirzepatide and semaglutide shows both medications reduce the risk of major cardiovascular events. The study highlights the early onset of cardioprotective effects, suggesting mechanisms beyond just weight loss. These findings support the integration of both agents into cardiovascular clinical practice.
Head-to-head evidence comparing the cardioprotective effects of tirzepatide and semaglutide is provided in a recent study from Mass General Brigham. According to the research, both drugs decreased the risk of heart attack, stroke, and mortality from any cause. The findings were simultaneously presented at the American Heart Association Scientific Sessions 2025 and published in Nature Medicine.
Prior research has demonstrated semaglutide's protective effects against cardiovascular incidents such as heart attack and stroke. However, it remained uncertain whether tirzepatide, also frequently prescribed for type 2 diabetes, provided similar cardiovascular advantages.
Researchers utilized national claims databases to assess cardiovascular outcomes in nearly one million adults receiving tirzepatide, semaglutide, or other type 2 diabetes medications.
The study revealed a cardiovascular advantage for individuals with type 2 diabetes at risk for adverse cardiovascular events. Semaglutide reduced the risk of stroke and heart attack by 18 percent compared to sitagliptin, a diabetes medication with neutral cardiovascular effects. Tirzepatide treatment decreased the risk of stroke, heart attack, and death by 13 percent compared to dulaglutide, another GLP-1 receptor agonist available for many years. Health tracking apps like Shotlee can help monitor such health metrics.
According to Krüger, "Both drugs demonstrate significant cardioprotective effects. Our data also suggests that these benefits manifest early, implying that their protective mechanisms extend beyond weight loss." The precise biological mechanisms underlying these protective effects are still unknown.
Due to the recent availability of these medications, studies validating their cardioprotective mechanisms—especially those directly comparing the two primary GLP-1 agents, tirzepatide and semaglutide—are still limited.
Krüger stated, "According to recent database analyses presented by the respective manufacturers, each company's drug appears to reduce cardiovascular risk much more effectively than the competitor's." However, the study found only minor differences in cardiovascular protection between tirzepatide and semaglutide among at-risk populations, emphasizing that both agents offer protective benefits and could be incorporated into clinical cardiovascular practice.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from Technology Networks
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨